Results 31 to 40 of about 101,340 (329)

RGS4 regulates partial agonism of the M2 muscarinic receptor-activated K+ currents. [PDF]

, 2014
Partial agonists are used clinically to avoid overstimulation of receptor-mediated signalling, as they produce a submaximal response even at 100% receptor occupancy.
Chen, I-Shan, Furutani, Kazuharu, Inanobe, Atsushi, Kurachi, Yoshihisa   +3 more
core   +2 more sources

A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson's disease.

PLoS ONE, 2019
Schizophrenia and Parkinson's disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists ...
Ana Martínez, Ilich A Ibarra, Rubicelia Vargas   +2 more
doaj   +1 more source

TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg

Frontiers in Pharmacology, 2018
Trace-amine associated receptor 1 (TAAR1) is the best-characterized member of the family of TAARs. TAAR1 is broadly expressed in the brain, especially within the monoaminergic systems.
Jian-Feng Liu, Jian-Feng Liu, Jun-Xu Li
doaj   +1 more source

Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]

, 2010
Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika, Barone, Paolo, Bötzel, Kai, Campenhausen, Sonja von, Dodel, Richard, Eggert, Karla, Longo, Katia, Oertel, Wolfgang H., Reese, Jens P., Spiga, Giuseppe, Winter, Yaroslav   +10 more
core   +1 more source

Treatment of hyperprolactinemia: a systematic review and meta-analysis

Systematic Reviews, 2012
Background Hyperprolactinemia is a common endocrine disorder that can be associated with significant morbidity. We conducted a systematic review and meta-analyses of outcomes of hyperprolactinemic patients, including microadenomas and macroadenomas, to ...
Wang Amy T, Mullan Rebecca J, Lane Melanie A, Hazem Ahmad, Prasad Chaithra, Gathaiya Nicola W, Fernández-Balsells M, Bagatto Amy, Coto-Yglesias Fernando, Carey Jantey, Elraiyah Tarig A, Erwin Patricia J, Gandhi Gunjan Y, Montori Victor M, Murad Mohammad   +14 more
doaj   +1 more source

Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection

Nature Communications, 2020
Dopamine agonists increase brain glutathione levels. Here the authors identify noncanonical signalling by Nrf2 as a potential mechanism for the neuroprotective effects of dopamine D2 receptor activation.
Yao Wei, Ming Lu, Meng Mei, Haoran Wang, Zhitao Han, Miaomiao Chen, Hang Yao, Nanshan Song, Xiao Ding, Jianhua Ding, Ming Xiao, Gang Hu   +11 more
doaj   +1 more source

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report

Frontiers in Psychiatry, 2022
Prolactinomas are the most prevalent functional pituitary adenomas. They are usually treated clinically with dopamine agonists. The most widely used and suitable drug is cabergoline (CAB), a specific D2 dopamine agonists.
Ana Carolina Correa e Castro, Andressa Alexandre de Araujo, Mariana Coelho Botelho, João Bosco Nascimento, Rafaela Marchon de Souza, Monica Roberto Gadelha, Antonio E. Nardi, Alice Helena Dutra Violante   +7 more
doaj   +1 more source

Pharmacology of novel psychoactive substances [PDF]

, 2016
This PhD work consists of an in vitro and in vivo part. In the in vivo part, we investigated the role of dopamine in the acute clinical effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in healthy human subjects.
Rickli, Anna
core   +1 more source

Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist

Endocrine Connections, 2018
The dopaminergic treatment represents the primary treatment in prolactinomas, which are the most common pituitary adenomas and account for about 40% of all pituitary tumours with an annual incidence of six to ten cases per million population.
Anastasia P Athanasoulia-Kaspar, Kathrin H Popp, Gunter Karl Stalla   +2 more
doaj   +1 more source

A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease [PDF]

, 2013
Copyright © 2013 IBRO. Published by Elsevier Ltd.
Barak, Basu-Modak, Bishop-Bailey, Breidert, Chen, Chen, Chopra, Ciesielska, Czlonkowska, Dauer, Dehmer, Delerive, Desvergne, Devchand, Dong, Escribano, H.L. Martin, Hsieh, Hébert, Iwashita, Jackson-Lewis, K. Sathe, Kalinin, Kreisler, Long-Smith, Luquet, M.C. Nelson, Martin, McGeer, Mogi, Mogi, Nicolakakis, Niino, Nuber, P. Teismann, Pascal, Polak, R.B. Mounsey, R.M. Evans, Ricote, S. Mustafa, Santos, Schintu, Shearer, Shi, Storer, Sznaidman, Takahashi, Teismann, Tian, Wang, West, Wu, Xu, Xu, Yacoub, Yi   +56 more
core   +1 more source